Ripple Effects of a Post-Pandemic Study

The acute effects of the COVID pandemic only softened around three years ago. The World Health Organization declared the official end of the global health emergency on May 5, 2023, after 765 million confirmed cases. In its wake, the crisis had revealed many problems in our healthcare system.

To investigate those issues, Distinguished Professor at the CUNY Graduate School of Public Health & Health Policy Denis Nash and his team at the CUNY Institute for Implementation Science in Population Health (CUNY ISPH) collaborated with Pfizer on the 2024 study, Project PROTECTS. They used both at-home and laboratory (PCR) testing to investigate long-term effects of several respiratory illnesses.

PROTECTS followed a 2020 long-term project by CUNY ISPH called Project CHASING COVID, which also received funding from Pfizer. The scope of CHASING COVID was broad, but PROTECTS involved an even greater level of complexity. With just over 6,000 participants, the study was a feat that Nash’s team had never tackled.

“What Pfizer proposed to us was a big lift,” says Nash. The company asked the researchers to track participants every day from the onset of symptoms for 30 days. Nash continues, “That was an intensity and complexity of data collection we hadn’t done before… but we were willing to try.”

The cohort study – a community-based, participatory research project – relied on diligent reporting by subjects. They came from geographically diverse regions of the U.S., but most were united by their high risk of severe outcomes if they came down with a respiratory infection.

Participants were mailed test and nasal swab collection kits. After becoming symptomatic, they self-administered two at-home rapid tests, 48 hours apart. Researchers asked a subset to send nasal swabs to the lab for PCR testing. This was followed by 29 days of responding to structured prompts about their symptoms.

The study maintained a high retention rate. Of over 6,000, only a few participants dropped out over the study’s two years. This allowed for a high-quality, robust dataset that Nash’s team is still finalizing.

Only people with the most severe cases of respiratory illness seek medical care. With PROTECTS, Nash’s team explored how average or minor respiratory illness cases looked. They were also interested in the use and accuracy of at-home testing.

Additionally, the team measured the effects of antivirals on short- and long-term symptoms. The team will finish collecting that data in the fall, and they are already busy with analyses and scientific papers.

They recently presented their results thus far at the European Society of Clinical Microbiology and Infectious Diseases global conference in Munich. Days three and five of symptoms saw the highest number of moderate symptoms for COVID and influenza, respectively. By days 17 and 16 (again, respectively), most subjects reported no symptoms. At-home testing was least reliable for influenza B, at a 37% positive predictive value, or accuracy. For COVID, it was 98%.

The rate of longer-term symptoms seems to be about the same (around 15%) for COVID, flu, and respiratory syncytial virus (RSV). Nash highlights how “Long COVID” has been studied extensively, while research on post-acute outcomes for other respiratory infections is rare.

Conducting such a complex study on a digital platform was new to Nash’s team. Participants submitted their responses to prompts while the online platform guided them through data collection for six months after any infection. The researchers developed additional algorithms and stayed vigilant to prevent fraudulent participation, problems with the interface, and other technological challenges.

As they near the end of the project, Nash and his team are proud of their success in the data collection phase. They look forward to ways their methods can be implemented for different public health questions in the future.

“In the background, there’s always been the threat of another pandemic, for example the bird flu,” says Nash. He hopes that having an active test cohort in place will let researchers quickly adapt to new pathogens.

The model can inspire new methodologies of pandemic preparedness. COVID taught us that global health crises may not be predictable – epidemiologists must work to anticipate them.

By Laura Tamayo, CUNY Research in Focus. Reposted by permission.